Clinical trials: Severe Sepsis With Septic Shock
Septic Shock, Endotoxemia
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
- Trial name
- TIGRIS (NCT03901807)
- Testing
- Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
- Where
- 20 sites in United States
- Volunteers
- 157 people
- Sponsor
- Spectral Diagnostics (US) Inc.
Severe Sepsis, Septic Shock
Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP Trial)
The purpose of this trial is to determine the influence of colloid versus crystalloid volume resuscitation and of intensive vs conventional insulin therapy on morbidity and mortality of patients with severe sepsis and septic…
- Trial name
- NCT00135473
- Testing
- 10% Hemohes® (10% Hydroxyethyl starch), Sterofundin® (Ringer lactate solution), Actrapid® (Insulin)
- Where
- 16 sites in Germany
- Volunteers
- 600 people
- Sponsor
- SepNet - Critical Care Trials Group
Systemic Inflammatory Response Syndrome (SIRS), Sepsis
Application of Stimulated Immune Response Change to Predict Outcome of Patient With Severe Sepsis
Persistence of a marked compensatory anti-inflammatory innate immune response after an insult is termed immunoparalysis. There is no biomarker available to determine the immune status of patient.
- Conditions
- Systemic Inflammatory Response Syndrome (SIRS), Sepsis, Severe Sepsis, Septic Shock
- Trial name
- SIRCSS (NCT02887274)
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Chang Gung Memorial Hospital
Severe Sepsis, Septic Shock
Comparison of Pediatric Septic Shock Treatment With and Without Central Venous Oxygen Saturation Monitoring
The purpose of this study was to compare ACCM/PALS guidelines performed with and without central venous oxygen saturation monitoring on the morbidity and mortality rate of children with severe sepsis and septic shock.
- Trial name
- NCT00407823
- Testing
- Central venous oxygen saturation continuous monitoring
- Where
- 2 sites in Brazil
- Volunteers
- 268 people
- Sponsor
- University of Sao Paulo
Septic Shock, Severe Sepsis
Autonomic Nervous System Alteration Induce by Sepsis: Assessment and Prognosis Impact
Severe sepsis and septic shock are causes of admission in intensive care units.Modification of natriuretic peptid including NT-proBNP and cardiac autonomic nervous system alteration are reported in sepsis shock and severe sepsis…
- Trial name
- SNA&Sepsis (NCT00835913)
- Where
- France
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Liver Cirrhosis, Septic Shock
Terlipressin in Septic Shock in Cirrhosis
Septic shock is a frequent and severe complication in cirrhosis. Current mortality rate ranges between 50 and 80% of cases. Refractory shock, hepatorenal failure and variceal bleeding are the main causes of death of these…
- Trial name
- NCT00628160
- Testing
- Terlipressin, alpha adrenergic drugs
- Where
- Spain
- Volunteers
- 72 people
- Sponsor
- Hospital Clinic of Barcelona
Severe Sepsis, Septic Shock
Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis
The overall purpose of the study is to determine whether either of the Improved Response Polymorphisms (IRPs) individually predicts a differential DrotAA treatment effect in patients with severe sepsis and high risk of death.
- Trial name
- NCT01486524
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 3,000 people
- Sponsor
- Sirius Genomics Inc.
Polyneuropathies, Septic Shock
Electrical Muscle Stimulation in the Development of Acquired Weakness in Patients With Severe Sepsis and Septic Shock
The aim of this study is to compare the effect of EMS and conventional physical therapy on strength and muscle mass and development in adult patients with severe sepsis and septic shock.
- Conditions
- Polyneuropathies, Septic Shock, Muscle Weakness
- Trial name
- NCT03765489
- Testing
- electrical muscle stimulation, conventional physical therapy
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Chile
Sepsis, Septic Shock
Vitamin C & Thiamine to Treat Sepsis and Septic Shock
Investigators propose to investigate the use of IV vitamins B1 and C in a randomized, double-blinded, prospective trial to determine if these medications decrease mortality rates in patients with severe sepsis or septic shock.
- Trial name
- NCT03592277
- Testing
- Vitamin C, Vitamin B1
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Trinity Health Of New England
Severe Sepsis With Septic Shock, Severe Sepsis Without Septic Shock
Long-term Cognitive and Cerebral Changes in Sepsis Survivors and Their Predictors
The main goals of this study are to provide a cognitive, neurological, brain morphological, and serological profile of sepsis survivors in order to make long-term prognosis of recovery and estimate the need for rehabilitation…
- Trial name
- BonSEP (NCT02339649)
- Testing
- Blood Sample, Neurocognitive Assessment, Resting State EEG
- Where
- 2 sites in Germany
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- German Center for Neurodegenerative Diseases (DZNE)
Severe Sepsis, Septic Shock
Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock
The purpose of this study is to evaluate the pharmacokinetics of pioglitazone and to determine the effect on inflammatory biomarkers for pioglitazone in patients with severe sepsis and septic shock.
- Trial name
- NCT01352182
- Testing
- Pioglitazone hydrochloride
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Severe Sepsis With Septic Shock, Severe Sepsis Without Septic Shock
Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis
Sepsis is a clinical syndrome which infection trigger systemic inflammatory response. Uncontrolled inflammatory process leads to multiple organ dysfunction and cause early mortality in severe sepsis.
- Trial name
- NCT02135770
- Testing
- Unfractionated heparin
- Where
- Indonesia
- Volunteers
- 115 people
- Sponsor
- Universitas Indonesia
Severe Sepsis, Septic Shock
Investigate the Activity of Endotoxin in Severe Sepsis
Endotoxin is the major mediator of gram-negative bacteria which cause the systemic inflammation and result in microcirculatory dysfunction, and it leads to multiple organ dysfunction and death in patients with severe sepsis and…
- Trial name
- NCT01957254
- Where
- Taiwan
- Volunteers
- 2 people
- Sponsor
- National Taiwan University Hospital
Sepsis, Severe Sepsis
The Effects of Eicosapentaenoic Acid (EPA), Gamma-Linolenic Acid (GLA) and Antioxidants in the Treatment of Sepsis
The scope of this clinical study is to evaluate the possible role of an enteral formulation enriched with EPA, GLA and Antioxidants in patients diagnosed in the early stages of sepsis despite mechanical ventilation requirements…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- NCT00329680
- Testing
- Eicosapentaenoic acid, Gamma-Linolenic Acid and Antioxidant Vitamins, Standard ICU enteral diet, isocaloric to the study diet
- Where
- 12 sites in Brazil
- Volunteers
- 115 people
- Sponsor
- Fernandes Tavora Hospital
Severe Sepsis, Septic Shock
Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock
Sepsis is a significant cause health care expenditure and carries an extremely high rate of morbidity and mortality if not treated appropriately.
- Conditions
- Severe Sepsis, Septic Shock, Bacteremia
- Trial name
- NCT01867905
- Where
- 7 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- University of British Columbia
Severe Sepsis, Septic Shock
Volume Replacement With Albumin in Severe Sepsis
BACKGROUND The association between mortality and hypoalbuminemia has been observed in several diseases. Nonetheless, the efficacy of albumin on survival in critically ill patients is controversial.
- Trial name
- ALBIOS (NCT00707122)
- Testing
- Albumin and Crystalloids, Crystalloids
- Where
- Italy
- Volunteers
- 1,818 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Systemic Inflammatory Response Syndrome (SIRS), Sepsis
Application of Biomarkers Change to Predict Outcome of Patient With Severe Sepsis
In 2004, the Surviving Sepsis Campaign (SSC) introduced guidelines for the management of severe sepsis and septic shock, as well as strategies for bedside implementation.
- Conditions
- Systemic Inflammatory Response Syndrome (SIRS), Sepsis, Severe Sepsis, Septic Shock
- Trial name
- BCSS (NCT02871895)
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Chang Gung Memorial Hospital
Sepsis, Severe, Sepsis
Microcirculation Properties of Albumin for Fluid Resuscitation in Septic Shock
The sublingual microcirculation is impaired in sepsis and septic shock. Sidestream dark field imaging technology has been developed into a clinical tool to help the clinician assess the microcirculation at the bedside.
- Conditions
- Sepsis, Severe, Sepsis, Septic Shock
- Trial name
- NCT05357339
- Testing
- 20% Albumin, Crystalloid
- Where
- Ireland
- Volunteers
- 100 people
- Sponsor
- Rachael Cusack
Severe Sepsis, Septic Shock
A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock
The primary purpose of this study to evaluate the effect of two different doses of AZD9773 (CytoFab™) versus placebo on ventilator free days (VFDs) over the first 28 days after the start of dosing with AZD9773 in patients with…
- Trial name
- NCT01145560
- Testing
- AZD9773
- Where
- 52 sites in Australia, Belgium and 5 more
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Severe Sepsis, Septic Shock
Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis
The purpose of this study is to determine whether BMS-936559 is safe and has the desired pharmacologic activity in patients who have severe sepsis.
- Trial name
- NCT02576457
- Testing
- BMS-936559
- Where
- 13 sites in United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb